A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort

Yasemin Cag1,2 · Sacit Icten3 · Burcu Isik-Goren1 · Naciye Betul Baysal1 · Begum Bektas1 · Ece Selvi4 · Sinar Ergen4 · Ozlem Aydin4 · Ayse Canan Ucsik4 · Fatma Yilmaz-Karadag4 · Hulya Caskurlu1 · Tulin Akars Ayazoglu · Hasan Kocoglu6 · Sinan Uzman5 · Muge Nural-Pamukcu5 · Ferhat Arslan1 · Gurhan Bas7 · Mahmut Tuyar Kalcioğlu8 · Haluk Vahaboglu1

Received: 19 May 2020 / Accepted: 24 August 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract
This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital. During the study period, 2043 patients with suspected COVID-19 were admitted to the emergency department. Molecular tests indicated that 475 of these patients tested positive for COVID-19. We administered hydroxychloroquine plus doxycycline to mild cases (isolated at home) for 3 days and lopinavir plus doxycycline to moderate and severe cases (hospitalized) for 5 days. The overall case fatality rate was 4.2% (20/475).

Keywords Doxycycline · Favipiravir · Lopinavir · Hydroxychloroquine · COVID-19

Introduction
Since the first report in December 2019 from Wuhan, Hubei Province, China, the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly worldwide [1]. Available data indicate that the clinical course and outcome of SARS-CoV-2 are much milder than those of SARS-CoV and MERS-CoV [2]. However, the socioeconomic consequences of the SARS-CoV-2 pandemic are enormous [3]. The false news regarding the clinical course and fatality rates triggered a global panic epidemic which has spread even faster than the virus. Social panic has the potential to accelerate the expected health burden of the disease [4].

Social panic causes excess inpatient capacity in hospitals as the number of individuals with mild nonspecific symptoms has been increasingly hospitalized. Controlling adverse outcomes of the disease and the panic among the public and healthcare staff depends on running an effective triage and management algorithm.

This manuscript aims to present a treatment algorithm we applied to manage COVID-19 patients admitted to our hospital and describe the characteristics of COVID-19 patients and the outcomes of the algorithm. This single-center, retrospective observational study was conducted in the Istanbul Medeniyet University Goztepe EA Hospital, a 600-bed affiliated hospital located in the Anatolian side of Istanbul. We...

1 Department of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
2 Istanbul Medeniyet Universitesi Goztepe Egitim ve Arastirma Hastanesi, Enfeksiyon Hastaliklari Klinigi, Dr. Erkin Caddeesi, 34722, Kadikoy, Istanbul, Turkey
3 Department of Pulmonary Medicine, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
4 Department of Infectious Diseases and Clinical Microbiology, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
5 Department of Anesthesiology and Reanimation, Istanbul Medeniyet University Goztepe Training and Research Hospital, Istanbul, Turkey
6 Department of Anesthesiology and Reanimation, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
7 Department of General Surgery, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
8 Department of Otorhinolaryngology, Istanbul Medeniyet University Faculty of Medicine, Istanbul, Turkey
obtained ethical approval from the Institute Ethics Committee, and signed informed consent was waived (2020/0193).

A case was defined as a patient with an epidemiologic risk factor who had body temperature of \( \geq 38 \, ^{\circ}C \) and/or respiratory system symptoms which cannot be fully explained by any other condition or disease (based on WHO approach). A mild case was defined to have no signs of respiratory dysfunctions, while a moderate case had any sign of respiratory dysfunction, and a severe case had acute respiratory failure (ARF) and required ICU support either via invasive or noninvasive means. Noninvasive ventilation support was administered with high-flow masks. Respiratory dysfunction was assessed in a patient having any of the following: (a) shortness of breath, (b) respiration rate of \( \geq 23 \) breaths per minute, and (c) \( O_2 \) saturation \(< 94\) in ambient air.

Hydroxychloroquine 200 mg, lopinavir 400 mg, and doxycycline 100 mg were all orally administered twice daily as recommended.

We managed COVID-19 patients with a 3-step treatment approach in our institute. First, mild cases were isolated at home and prescribed with hydroxychloroquine plus doxycycline for 3 days. Second, moderate to severe cases were hospitalized and prescribed with a regimen of lopinavir plus doxycycline plus ceftriaxone for 5 days. Third, we used a salvage therapy for patients who did not respond to or whose conditions worsened under the lopinavir treatment. This therapy involved the oral administration of favipiravir 600 mg twice daily after two loading doses.

We performed all statistical analysis using the open-source R software (R Foundation for Statistical Computing, Vienna, Austria) [5–7].

Results and discussion

From March 22 to April 22, 2020, 2043 patients were admitted to our emergency department, presenting symptoms compatible with those stated in our case definition. PCR was positive for nasopharyngeal samples of 475 adult patients. We run a 3-step treatment algorithm, and our approach is displayed in Fig. 1. We hospitalized moderate to severe cases and administered lopinavir combined with doxycycline and ceftriaxone to 343 patients, among whom 161 had positive PCR test results (161/343, 46.9%). Unfortunately our lab ceased respiratory vi-

Table 1 presents the baseline characteristics of PCR positive patients. We administered our standard regimen, lopinavir plus doxycycline plus ceftriaxone, to these hospitalized patients. Among 161 cases, 31 required ICU support, and 20 deceased during ICU stay. However, 12 of these patients were severe at admittance. Of these nine patients immediately admitted to the ICU, five of whom died. Three other patients transferred to the ICU on the second day of admittance to the hospital also died.

Of the 161 hospitalized patients, 149 acquired lopinavir for at least 2 days before being admitted to the ICU. Only 12.7\% (19/149) required ICU support with lopinavir treatment, two patients suddenly died, and 128 patients recovered from the disease.

Only 24\% (38/158) of patients had a fever (\( \geq 38 \, ^{\circ}C \)). Deceased patients were older, had a higher prevalence of hypertension, and had a higher neutrophil counts than the others, while their lymphocyte counts, platelet counts, and levels of oxygen saturation in ambient air were lower. No difference was observed between two genders. Deceased patients had shorter elapsed time between the onset of symptoms and hospitalization.

This study presents a 3-step treatment protocol to manage COVID-19 patients. We administered hydroxychloroquine to mild cases isolated at home, lopinavir plus doxycycline to hospitalized moderate to severe cases, and favipiravir in the salvage treatment. We were able to run this approach smoothly.

To our best knowledge, this study is the very first to report data from Istanbul, Turkey. More importantly, our data present the results of a unique combination of lopinavir and doxycycline.
We administered hydroxychloroquine to mild cases for only 3 days because of its potential side effects on cardiac functions [9]. The cardiac effects of hydroxychloroquine are demonstrated to depend on the accumulation of the drug and mostly start on the third day of the usage. These effects are more prominent among critically ill patients [10].

Fig. 1 The algorithm we applied in emergency department to manage outpatients with COVID-19.

Fig. 2 The epidemic curve showing PCR negative and positive patients. It is noteworthy that the number of PCR positive patients decreases over time, but due to the ongoing fear in the population, the number of PCR negative patients do not decrease proportionally.
We administered lopinavir to moderate to severe cases for 5 days. Clinical trials demonstrated its effectiveness in the treatment of patients with SARS and MERS [11]. Molecular analysis indicates that lopinavir has a potential role in inhibiting SARS-CoV-2 protease, thereby blocking viral replication [12]. A recent study found a limited benefit of lopinavir compared with the standard of care treatment [13]. However, this study had substantial methodologic limitations, which raises questions about its conclusions.

We supplemented doxycycline to both lopinavir and hydroxychloroquine due to its immunomodulatory activity. Recent findings revealed the adverse effect of dysregulated immunity on the outcome of COVID-19 patients [14]. Doxycycline induces the suppressor of cytokine signaling (SOCS) proteins, a regulatory system on cytokine release [15]. Evidence accumulates that SOCS proteins, mainly SOCS-3 protein, prevent interleukin- and interferon-associated toxicity [16]. Notably, in the early stage of the disease, when there are enough healthy cells in the bronchi and alveoli, doxycycline might have some effect on preventing the upcoming cytokine storm. Doxycycline had been successfully used in dengue hemorrhagic fever due to its immunomodulatory activity [17]. However, we also consider covering other etiologies of community-acquired pneumonia. At admission, it is challenging to differentiate COVID-19 from other etiologies of pneumonias, such as mycoplasma infections [18].

However, the study has several limitations which require to be addressed. The major limitation of this study lies in its retrospective and single-center nature which is a source of selection bias to evaluate the efficacy of a treatment. In our study, a considerable number of died patients were extremely severe at admittance and so directly allocated to ICU care. A 3-step treatment algorithm ran smoothly in our hospital. We concluded that home isolation of mild cases is an effective means to manage the burden of disease, while lopinavir plus doxycycline is an alternative to current treatment regimens for COVID-19. However, in future epidemics, isolation of mild cases at new-settled fever clinics should be considered which might serve better to mitigate epidemics [19].

Compliance with ethical standards

Conflicts of interest The authors declare that they have no conflicts of interest.

| Table 1 Baseline descriptive parameters of PCR positive hospitalized patients |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Factors\(^1\)                  | All N = 161     | Survived N = 141 | Died N = 20     | p       | N   |
| Female gender                 | 77 (47.8%)     | 67 (47.5%)      | 10 (50.0%)      | 1.000   | 161 |
| Age (years)                   | 61.0 [48.0;72.0] | 59.0 [48.0;70.0] | 74.5 [67.5;85.5] | <0.001 | 161 |
| Hypertension                  | 57 (35.4%)     | 43 (30.5%)      | 14 (70.0%)      | 0.000   | 161 |
| Diabetes                      | 32 (20.6%)     | 26 (19.1%)      | 6 (31.6%)       | 0.340   | 155 |
| ACEI: yes                     | 32 (20.6%)     | 26 (19.1%)      | 6 (31.6%)       | 0.285   | 158 |
| Elapsed time to ICU (days)    | 3.00 [0.00; 6.00] | 3.00 [0.00; 6.00] | 3.00 [0.00; 6.00] | 0.084   | 31  |
| Hospital stay (days)          | 2.00 [1.00; 5.00] | 3.00 [1.00; 5.00] | 1.50 [1.00; 9.25] | 0.966   | 161 |
| WBC (\(\times 10^9/L\))       | 6.15 [4.80; 7.80] | 6.10 [4.70; 7.65] | 7.09 [5.40; 11.1] | 0.080   | 158 |
| PLT (\(\times 10^9/L\))       | 180 [138; 234] | 181 [145; 236] | 46 [21; 143] | 0.104   | 158 |
| EOS (\(\times 10^9/L\))       | 0.01 [0.00; 0.03] | 0.01 [0.00; 0.03] | 0.01 [0.00; 0.03] | 0.285   | 158 |
| NEUT (\(\times 10^9/L\))      | 4.44 [3.05; 5.67] | 4.26 [2.87; 5.58] | 5.28 [4.43; 8.14] | 0.007   | 158 |
| LYM (\(\times 10^9/L\))       | 1.20 [0.90; 1.60] | 1.20 [0.10; 1.69] | 0.90 [0.70; 1.30] | 0.029   | 158 |
| pH\(^2\)                      | 7.42 [7.38; 7.45] | 7.41 [7.35; 7.44] | 7.44 [7.41; 7.47] | 0.061   | 138 |
| pO2                           | 35.8 [25.8; 48.4] | 34.9 [22.8; 48.4] | 38.2 [31.9; 56.2] | 0.212   | 143 |
| pCO2                          | 44.8 [40.0; 48.1] | 44.8 [40.1; 48.7] | 43.0 [35.3; 47.8] | 0.273   | 143 |
| Temperature                   | 37.0 [36.6; 37.9] | 37.0 [36.6; 37.7] | 37.5 [36.9; 38.3] | 0.085   | 158 |
| High fever (≥ 38 °C)          | 38 (24.1%) | 30 (21.4%) | 8 (44.4%) | 0.042   | 158 |
| O2 saturation                 | 95.0 [93.0; 96.9] | 95.0 [93.0; 96.0] | 88.0 [85.5; 94.0] | <0.001   | 159 |
| Respiration rate per min      | 21.0 [20.0; 25.0] | 21.0 [20.0; 24.2] | 22.0 [20.0; 26.0] | 0.407   | 149 |
| Elapsed time to hospitalization | 5.00 [3.00; 7.00] | 6.00 [3.00; 8.00] | 4.00 [2.00; 5.50] | 0.015   | 152 |
| Intubated                     | 27 (16.6%) | 10 (7.09%) | 17 (85.0%) | <0.001   | 161 |

\(^1\) ACE inhibitor, angiotensin converting enzyme inhibitor; elapsed time to ICU, time between hospitalization and ICU admission; O2 saturation, saturation in ambient air; high fever, fever ≥ 38 °C; elapsed time to hosp., time between onset of symptoms and hospitalization

\(^2\) Blood gases were mostly obtained during hospital stay not at admission
Ethics approval  The study protocol was approved by the Clinical Research Ethics Committee of Istanbul Medeniyet University Goztepe Training and Research Hospital, and signed informed consent was waived (2020/0193).

References

1. Zhu N, Zhang D, Wang W, Li XX, Yang B, Song J, et al. A Novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med [Internet] 2020 20 [cited 2020 12];382:NEJMoa2001017. https://doi.org/10.1056/NEJMoa2001017
2. Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 332. https://doi.org/10.1001/jama.2020.2648
3. Ioannidis JPA (2020) Coronavirus disease 2019: the harms of exaggerated information and non-evidence-based measures. J Clin Investig:13222. https://doi.org/10.1111/jci.13222
4. Martin S, Karafillakis E, Preet R, Wilder-Smith A The pandemic of social media panic travels faster than the COVID-19 outbreak. Artic J Travel Med [Internet] 2020 [cited 2020 26];https://doi.org/10.1093/jtm/taaa031/5775501
5. Harrell Jr FE rms: Regression modeling strategies [Internet]. 2019; https://cran.r-project.org/package=rms . Accessed 13 May 2020
6. Subirana I, Sanz H, Vila J (2014) Building bivariate tables: the {compareGroups} package for {R}. J Stat Softw [Internet] 57:1–16 http://www.jstatsoft.org/v57/i12/. Accessed 13 May 2020
7. Gordon M Gmisc: Descriptive statistics, transition plots, and more [Internet]. 2020; https://cran.r-project.org/package=Gmisc . Accessed 13 May 2020
8. Toscano G, Pamerima G, Bajjalagia S, Ruiz L, Invernizzi P, Cuzzoni MG et al (2020) Guillain-Barré syndrome associated with SARS-CoV-2. Engl J Med 382:2574–2577. https://doi.org/10.1056/NEJMc2002019
9. Fernandes FP, Silva EP, Martins RR, Oliveira AG (2018) QTc interval prolongation in critically ill patients: Prevalence, risk factors and associated medications. PLoS One [Internet] 13:e0199028. https://doi.org/10.1371/journal.pone.0199028
10. Chorin E, Dai M, Shulman L, Wadhawan L, Cohen RB, Barhbaia C et al (2020) The QT interval in patients with SARS-CoV-2 infection treated with hydroxychloroquine/azithromycin. https://doi.org/10.1101/2020.04.02.20047550
11. Yao T-T, Qian J-D, Wang Y, Jiang Y, Yang G-Q (2020) A systematic review of lopinavir treatment for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease-19 treatment option. J Med Virol:1–8 https://doi.org/10.1002/jmv.25729
12. Dayer MR, Taha Fassabi S, Dayer MS (2017) Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study. Arch Clin Med Dis 12. https://doi.org/10.5812/archcid.13823
13. Cao J, Wang Y, Wan D, Liu W, Wang J, Fan G et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med [Internet]. https://doi.org/10.1056/NEJMoa2001282
Nicholls M, Poon LLM, Lee KC, Ng WF, Lai ST, Leung CY et al (2003) Lung pathology of fatal severe acute respiratory syndrome. Lancet 361:1773–1778. https://doi.org/10.1016/S0140-6736(03)31417-2
14. Song MM, Shuai K (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273: 35056–35062. https://doi.org/10.1074/jbc.273.52.35056
15. Karlsson AE, Rönng SG, Lindberg K, Johannessen J, Galsgaard ED, Pociot F et al (2001) Suppressor of cytokine signaling 3 (SOCS-3) protects β-cells against interleukin-1β- and interferon-γ-mediated toxicity. Proc Natl Acad Sci U S A 98:12191–12196. https://doi.org/10.1073/pnas.211445998
16. Fredeking T, Zavala-Castro J, Gonzalez-Martinez P, Moguel-Rodriguez W, Sanchez E, Foster M et al (2015) Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Pat Antinfect Drug Discov 10:51–58. https://doi.org/10.2174/1574891x10666150410153839
17. Dai W, Zhang H, Yu J, Xu Y, Chen H, Luo S et al (2020) CT imaging and differential diagnosis of COVID-19. Can Assoc Radiol J 71:084653712091303. https://doi.org/10.1177/084653712091303
18. Tang L, He Y, Bai F, Luo B. The role of fever clinic during the COVID-19 pandemic: a case study of 1034 febrile patients. 2020 [cited 2020 12];https://www.researchsquare.com/article/rs-28368/latest.pdf. Accessed 13 Aug 2020

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.